Zydus Cadila announced that it has successfully completed a Phase 2 clinical trial in CoVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHepTM'. The study so far has indicatedthat Pegylated Interferon alpha-2bcould have a beneficial impact on the patient suffering from moderate COVID 19disease by reducing theirviral loadhelping in better disease managementsuch asreduced duration of oxygen support.Moreover, a single dose therapy will improvecompliance and also make it highlyaffordable for patients
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
